Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read More
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read More
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read More
Kazia Therapeutics has announced that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE, a leading European drug discovery and development company.
Read More
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreThomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read More
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read More
ShareCafe’s Tim McGowen spoke with Steve Promnitz, CEO of Lake Resources (ASX: LKE) about what VW’s announcement that it would build six new battery factories in Europe means for the lithium space.
Read More
Advances in genome sequencing and in other healthcare technologies have played a critical role in controlling the COVID-19 pandemic. This article from Pengana Capital explains how.
Read More
Australian biotechnology company Antisense Therapeutics Limited recently appointed Gil Price M.D. as a Consultant Medical Director. He spoke with with ShareCafe’s Tim McGowen about his new role.
Read More
GeneticSignatures (ASX: GSS) a specialist molecular diagnostics (MDx) company, plans to leverage its existing suite of real-time screening products into an expanding customer base.
Read More
Australian oncology-focused company, Kazia Therapeutics has just announced a license agreement with Swedish speciality pharmaceutical company Oasmia Pharmaceutical for its ovarian cancer drug Cantrixil.
Read More
Hearing implant maker, Cochlear is making a return to paying dividends after the impact of COVID, the pandemic and social distancing rules damaged its 2020 finances.
Read More
COVID has been good news for two of Australia’s health giants – Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read More
Noxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. The company’s CEO Dr Graham Kelly tells us more.
Read More
Alex Cook from BetaShares examines the role robotics and A.I. have played not only in developing a vaccine but also in its distribution.
Read More
Growth in masks and accessories has prevailed for ResMed despite pandemic-induced restrictions, although cycling the surge in ventilator sales from early 2020 will be a challenge.
Read More
Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function.
Read More
In this video, immunotherapy pioneer Immutep’s (ASX: IMM) CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments.
Read More
Mark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.
Read More
With the COVID-19 pandemic dominating markets, politics, and everyday life, it’s no wonder that Warren Buffett has moved heavily into pharma and medical stocks in the quarterly latest fund manager filing with the US Securities and Exchange Commission.
Read More
Pfizer and BioNTech have announced preliminary data from a late-stage clinical trial for their COVID-19 vaccine candidate, and the results were better than expected. Matt Peron and Andy Acker from Janus Henderson Investors explain what this means for the fight to end the pandemic and the next leg of the market cycle.
Read More
With Alphinity celebrating its 10th anniversary we have explored what has happened in the healthcare sector in the decade since Alphinity was first established.
Read More
Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its novel candidate to treat a genetic muscular disorder that affects only boys and is regressive, fatal, and poorly treated.
Read More
As an analyst who follows biopharma companies, I take an interest in the US Food and Drug Administration (FDA), while as an American/Australian, US politics, particularly, in the days of Trump, is also an interest. Then, there is an ASX-listed cellular therapy company called Mesoblast (ASX:MSB), which I have followed pretty much since it listed in 2004.
Read More
Drugs and biologics often end up with multiple names as they travel through the development and commercialisation. It can all get very confusing and even more so after the therapeutic is on the market but turns out to have multiple different names across multiple different jurisdictions.
Read More
